Claims

[Claim 1]

A solid supplement comprising the following components (A) and (B):

(A) sphingomyelin in an amount of from 0.15 to 7 % by mass; and

(B) phosphatidyl inositol or a salt thereof,

wherein a mass ratio of a content of phosphatidyl inositol or the salt thereof (B) in terms of phosphatidyl inositol content to a content of sphingomyelin (A) in the solid supplement, i.e., [(B)/(A)], is from 0.05 to 3.

[Claim 2]

The solid supplement according to claim 1, wherein the content of phosphatidyl inositol or the salt thereof (B) in terms of phosphatidyl inositol content in the solid supplement is from 0.02 to 10 % by mass.

[Claim 3]

The solid supplement according to claim 1 or 2, wherein a content of palmitic acid in the total fatty acid constituents of sphingomyelin (A) is 50 % by mass or less.

[Claim 4]

The solid supplement according to any one of claims 1 to 3, further comprising (C) an excipient.

[Claim 5]

The solid supplement according to claim 4, wherein a content of the excipient (C) in the solid supplement is from 25 to 99.8 % by mass.

[Claim 6]

The solid supplement according to claim 4 or 5, wherein the excipient (C) comprises a sugar alcohol.

[Claim 7]

The solid supplement according to any one of claims 4 to 6, wherein the excipient (C) comprises one or more selected from the group consisting of maltitol, erythritol and xylitol.

[Claim 8]

The solid supplement according to claims 7, wherein a content of the one or more selected from the group consisting of maltitol, erythritol and xylitol in the excipient (C) is from 3 to 75 % by mass.

[Claim 9]

The solid supplement according to any one of claims 1 to 8, wherein the supplement is a tablet and the weight per tablet is from 0.1 to 2 g.

[Claim 10]

The solid supplement according to any one of claims 1 to 9, wherein the supplement is a chewable tablet or a troche.

[Claim 11]

The solid supplement according to claim 9 or 10, wherein a tablet hardness is from 30 to 140 N.

Claims

[Claim 1]

A solid supplement comprising the following components (A), (B) and (C):

(A) sphingomyelin in an amount of from 0.15 to 7 % by mass;

(B) phosphatidyl inositol or a salt thereof; and

(C) an excipient;

wherein a mass ratio of a content of phosphatidyl inositol or the salt thereof (B) in terms of phosphatidyl inositol content to a content of sphingomyelin (A) in the solid supplement, i.e., [(B)/(A)], is from 0.05 to 3, and the excipient (C) comprises a sugar alcohol.

[Claim 2]

The solid supplement according to claim 1, wherein the content of phosphatidyl inositol or the salt thereof (B) in terms of phosphatidyl inositol content in the solid supplement is from 0.02 to 10 % by mass.

[Claim 3]

The solid supplement according to claim 1 or 2, wherein a percentage of palmitic acid in the total fatty acid constituents of sphingomyelin (A) is 50 % by mass or less.

[Claim 4]

The solid supplement according to any one of claims 1 to 3, wherein a content of the excipient in the solid supplement (C) is from 25 to 99.8 % by mass.

[Claim 5]

The solid supplement according to any one of claims 1 to 4, wherein a content of the sugar alcohol in the excipient (C) is from 3 to 75 % by mass.

[Claim 6]

The solid supplement according to any one of claims 1 to 5, wherein the excipient (C) comprises one or more selected from the group consisting of maltitol, erythritol and xylitol.

[Claim 7]

The solid supplement according to any one of claims 1 to 6, wherein the supplement is a tablet and the weight per tablet is from 0.1 to 2 g.

[Claim 8]

The solid supplement according to any one of claims 1 to 7, wherein the supplement is a chewable tablet or a troche.

[Claim 9]

The solid supplement according to claim 7 or 8, wherein a tablet hardness is from 30 to 140 N.

[Claim 10]

The solid supplement according to any one of claims 1 to 9, wherein the solid supplement is manufactured by preparing a mixture of the sphingomyelin (A), the phosphatidyl inositol or a salt thereof (B) and optionally additives which is added as required, and then compression-molding the mixture.